First HER2 targeted Antibody Drug Conjugate Kadcyla, an Anti-Cancer Agent Approved for HER2-positive Inoperable or Recurrent Breast Cancer

Attached a press release by Chugai.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news